Drawing for CURADEL

USPTO serial 86716408

CURADEL

Reviewed by CopyMark Law Group

Reg. 5281759Status 702Renewal
Filing date
Status date
Registration date
Sep 5, 2017
Examiner
GRIFFIN, JAMES
Law office
Historical data usage

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with CURADEL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,795*

Plus Government fees of $3,250

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Susan B. Meyer

Susan B. Meyer Gordon Rees Scully Mansukhani LLP101 West Broadway, Suite 2000San Diego, CA 92101United States

Goods and services

ClassDescriptionStatusFirst use
005Contrast agents for use in surgical and medical imaging and visualization; fluorescent contrast agents for use in surgical and medical imaging and visualization; exogenous contrast agents for use in surgical and medical imaging and visualization; near-infrared contrast agents for use in surgical and medical imaging and visualization; exogenous near-infrared contrast agents for use in surgical and medical imaging and visualization; near-infrared contrast agents for use in surgical procedures; exogenous near-infrared contrast agents for use in surgical procedures; near-infrared contrast agents for use in medical imaging and visualization; exogenous near-infrared contrast agents for use in medical imaging and visualization; near-infrared contrast agents for use in real-time surgical imaging and visualization; exogenous near-infrared contrast agents for use in real-time surgical imaging and visualization, none of the foregoing being ophthalmic preparations, otorhinolaryngological preparations, or preparations for the treatment of inflammation; * none of the foregoing are for use in connection with wound management, medical dressing materials, haemostats, sealants, and blood clotting agents *ACTIVESep 1, 2016
010Medical and surgical equipment for use in surgical procedures, namely, cameras and near-infrared cameras, and operating software used therewith, all sold as a unit; medical and surgical equipment for use in medical procedures, namely, cameras and near-infrared cameras; medical and surgical equipment for use in medical imaging and visualization, namely, cameras and near-infrared cameras, and operating software used therewith, all sold as a unit, medical and surgical equipment for use in medical imaging and visualization, namely, visual wavelength imaging cameras, ultraviolet wavelength imaging cameras, radioscintigraphic detection hardware, optical lenses, image detectors, light sources, monitors, and operating software used therewith, all sold as a unit; medical and surgical equipment for use in medical imaging and visualization, namely, cameras and near-infrared cameras; medical and surgical equipment for use in real-time surgical imaging and visualization, namely, cameras and near-infrared cameras, and operating software used therewith, all sold as a unit; medical and surgical equipment for use in real-time surgical imaging and visualization, namely, cameras and near-infrared cameras; medical imaging and visualization systems consisting of imaging apparatus and operating software used therewith, all sold as a unit; surgical imaging and visualization systems consisting of imaging apparatus and operating software used therewith, all sold as a unit; real-time medical imaging and visualization systems consisting of imaging apparatus and operating software used therewith, all sold as a unit; real-time surgical imaging and visualization systems consisting of imaging apparatus and operating software used therewith, all sold as a unit; oncological imaging and visualization systems consisting of imaging apparatus and operating software used therewith, all sold as a unit; real-time oncological imaging and visualization systems consisting of imaging apparatus and operating software used therewith, all sold as a unitACTIVESep 1, 2016
035Providing consumer information in the field of cancer treatment and diagnosis via the Internet and social mediaACTIVESep 1, 2016
042Medical and scientific research services in the field of cancer treatment and diagnosisACTIVESep 1, 2016
044Providing health information in the field of cancer treatment and diagnosis via the Internet and social mediaACTIVESep 1, 2016

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 5, 2026REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Sep 5, 2026REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Sep 5, 2026REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Sep 5, 2026REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Mar 17, 2026NURCNOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED—
Feb 26, 2026A7OKAMENDMENT UNDER SECTION 7 - PROCESSED—
Feb 23, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Nov 17, 2025ES7RTEAS SECTION 7 REQUEST RECEIVED—
Mar 20, 2023NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Mar 20, 2023C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Mar 20, 2023APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Sep 6, 2022E815TEAS SECTION 8 & 15 RECEIVED—
Sep 5, 2022REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
May 19, 2021CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
May 19, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 19, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 19, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 19, 2021COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Sep 18, 2019CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Sep 18, 2019COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Sep 5, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 2, 2017SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Aug 1, 2017CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Jul 31, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 31, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 31, 2017ALIEASSIGNED TO LIE—
Jun 27, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 14, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 14, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 14, 2017CNRTSU - NON-FINAL ACTION - WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 14, 2017DOCKASSIGNED TO EXAMINER—
May 18, 2017CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
May 18, 2017COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Oct 25, 2016DOCKASSIGNED TO EXAMINER—
Oct 21, 2016SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Oct 20, 2016AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Oct 5, 2016IUAFUSE AMENDMENT FILED—
Oct 5, 2016EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Apr 5, 2016NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Feb 9, 2016NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 9, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 20, 2016NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 4, 2016PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Dec 16, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 25, 2015XAECEXAMINER'S AMENDMENT ENTERED—
Nov 25, 2015ALIEASSIGNED TO LIE—
Nov 25, 2015GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Nov 25, 2015GNEAEXAMINERS AMENDMENT E-MAILED—
Nov 25, 2015CNEAEXAMINERS AMENDMENT -WRITTEN—
Nov 24, 2015AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Nov 24, 2015PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Nov 18, 2015DOCKASSIGNED TO EXAMINER—
Aug 11, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—

Frequently asked questions

Related guidance